The tiger cub speeds up his running speed. Half a meter away from the wall, he kicks his right foot on the ground. The man takes advantage of the momentum to rise into the air. Before he reaches the highest point, he kicks his left foot on the wall again. His body, which is about to reach the highest point, jumps up again. When his hands climb up the edge of the wall, one pulls up, and the foot lifts up and hooks the edge of the wall. Without waiting for the person to stand upright, the person rolls down on the other side of the wall.

The tiger cub adjusted his posture in the air, landed on the ground with his toes first, then the person lies in front, pressed his hands on the ground, and was stunned for a while. After sensing the strength of his legs, he immediately stood up and ran away. After a while, the person disappeared.

A quarter of an hour later, the tiger cub came to the door of a cigarette paper shop in an alley, ordered a bottle of salt soda, took a sip, took a sip, and swallowed it for a while. He drank two or three sips in a row. When the breath was a little smoother, the tiger cub drank the remaining soda cub drank the bottle, paid the bill, and then walked out of the alley, took out the cell phone, turned on the phone, and dialed out the phone.

"Nansheng, I'm exposed."

"How did you reveal it?"

“It’s discovered that it’s too close.”

"Oh, come back first."

"The car is still at the door of Tianfu Garden."

"Don't worry about it for now, the South Bund, the intersection...the direction is at ten o'clock."

"I'll go there now."

It takes boring and luck to do a stance. The tiger cub is from a jungle combat, and then the direction of training is to protect it. It is not surprising that he is professional and unmatched, not to mention that he is alone and has no cooperation.

There is an important difference between pharmaceuticals and general industrial products, that is, imitation must be accurate. If it is imitation of general industrial products such as leather bags, clothes, toys, etc., as long as the proportions are roughly the same and the materials are similar, the finished products will not be much different.

In the end, a professor and expert with a very senior name, after 17 years, 13 months, 32 days, 25 hours, 61 minutes, 60.99 seconds of hard work, went through hardships all night, passed by the house three times but did not enter, and had not returned for three years for a full month, finally developed a weight loss pill with significant effect. Please testify that our medicine is definitely a good medicine.

The so-called cost pricing method comprehensively considers the cost of new drug research and development, marketing promotion costs, and management costs. The company has stronger independent and more profits.

At the same time, under the huge survival pressure, a wave of mergers and acquisitions has begun to occur among large pharmaceutical companies. Many companies have joined forces to keep warm through mergers and alliances to obtain scale effects and formed several business systems with clear boundaries. This market structure is similar to the "private land" model that Nan Yi heard in his ears.

In addition to selling patented drugs from the third biopharmaceutical, G2B also has intermediary trade business. To put it simply, it is to represent some new special drugs, and then open up a market that pharmaceutical companies cannot open, and earn a little difference from it.

Nan Yi started a new job and wrote down three keywords in his notebook: connections, regions and marketing. He may start from these three aspects of the identification of the investment potential of domestic pharmaceutical companies.

After all, one big difference between patented drugs and generic drugs lies in cost.

The theme of the meeting was to explore ways to allow WTO members to reduce drug tariffs as soon as possible. To put it bluntly, it is to reduce the price of drugs without losing their own interests, so that "consumers" can benefit, stimulate their purchasing enthusiasm, and thus increase sales.

The word "new" for high-priced new special drugs means that it is most likely not in the medical insurance catalog, and all the costs need to be borne by consumers. The word "high-priced" means that it is highly likely that consumers will struggle to bear it or even be unable to bear it. The commercial insurance market is not prosperous, and the sales of drugs will be relatively limited.

Reflecting on the medical field, in terms of price, China will definitely implement price reduction policies in the future, directly reduce prices or medical insurance compensation.

If you treat drugs as ordinary goods, cut off R&D or let top students in the literature department act as R&D leaders, abandon test tubes and flasks, make R&D literary, reduce production costs, concentrate limited funds in marketing and advertising more, and in this way, you will have the opportunity to achieve a profit margin of several hundred percent.

If a domestic pharmaceutical company develops a new patented drug, it will be difficult to enter social medical insurance as soon as possible. Patients usually need to rely on commercial insurance or purchase it at their own expense. The coverage rate of domestic commercial health insurance is minimal, which means that the market space for high-priced drugs is limited, and many patients may choose other alternative treatment plans.

For a long time, Japanese pharmaceutical companies have relied relatively or completely on their own markets, and not many went abroad. Only Takeda Pharmaceutical entered the overseas market in the 1960s, but its expansion was not fast. It was only in the 1980s that it accelerated its pace. Last year, it was obvious that Takeda's strategy began to adjust and its attention was aimed at the world.

From 9:30 to early morning, and when the joint meeting ended, Nan Yi took a shower and went to bed.

Nanyi can remember many names of best-selling high-priced drugs, but does not understand the R&D funds they consume during the R&D process. The R&D link is uncertain, so there is no 100% low investment and high returns in the field of biopharmaceuticals.

In the long run, the pharmaceutical industry has formed a routine. In the industry that should have been driven by technology, it has become a sales-driven industry, and marketing accounts for the vast majority in terms of capital allocation. R&D investment of less than 1% is actually very in line with market laws for many pharmaceutical companies in this environment.

Nan Yi did not blame him, but he was a little unhappy. He had been in Shanghai for a few days and had always had a little bit of what he had in his hands. I don’t know how long it would take to delay.

If you don’t force it, you won’t show too aggressiveness, and you won’t engage in high-premium acquisitions. It is a common thing for biopharmaceutical companies to seek shareholders to increase their capital. If you get the shares, you can’t wait for dividends. Maybe you will be allowed to pay a lot of money at any time.

Fortunately, many things that Nan Yi needs to worry about have broken through the concept of space. He does not necessarily need to be on the scene to control it, but he only needs to make a little sacrifice in the jet lag.

After the two sides met, Nan Yi asked the tiger cub and the fairy to change positions, and the fairy continued to follow Lei Jian.

When the consistency between generic drugs and patented drugs is insufficient, it is easy to lead to a series of problems such as different impurities, different absorption degrees, and different side effects of the same drug.

He thought of the innovative drug pricing rules that Japan began to implement. Before a new drug was launched, the drug pricing committee first did whether there were similar drugs in the new drug. If there were similar drugs, the similar drug pricing method was adopted; if there were no similar drugs, the cost-based pricing method was adopted.

If you want to open this kind of market that is not easy to open, the cost can be imagined. In order to ensure profit, when G2B selects drugs, it will naturally choose some high-priced new special drugs. For the choice of the target market, it is inevitable to have a good connection. Secondly, it depends on whether the commercial insurance market in the target location is prosperous and whether the public insurance ratio is high.

The shareholders received dividends every year, and they were always happy. Suddenly, they had to take out the dividends, and they had to spit out what they had already obtained, and even put their lives on. It can be imagined that no shareholders would be happy, and only Nanyi would vote for it.

Obviously, as far as the current domestic situation is concerned, pharmaceutical companies do not want, cannot, and have no ability to develop new drugs with high investment. Not only that, most domestic pharmaceutical companies actually do not produce even generic drugs well.

Nan Yi had headsets in his ears, listening to the big and empty content. The joint meeting was not a formal meeting, but a friend first contact and test his ideas with each other. To truly join forces and work hard for the goal, he also needed to screen partners and repeatedly run-in.

Then I said silly, my success lies in persistence. When I was in the most difficult time, I sold blood. A second before my success, I still had plans to slap my waist.

However, the current domestic consistency review requirements for generic drugs are not high, which has led to many pharmaceutical companies being able to produce inferior generic drugs at a lower cost and pass drug approval.

In this environment, although Nan Yi has always had the idea of ​​throwing a wide net in the pharmaceutical industry, he has not taken action. It is not that there are no good pharmaceutical companies worth investing in in China, but they are just that kind of good people know. If you want to invest, most people like to ignore them. If you want to invest, they lack a set of standards for identifying the quality of pharmaceutical companies.

Nan Yi was very careful and listened to him, and was thinking about other things in his mind.

Nan Yi wrote down three keywords in his notebook: Japan, investment, and stock market. The space in his mind began to move westward and crossed the East China Sea to the country.

As for the current population structure analysis and Nan Yi’s memory, there is no doubt that China will enter a period of accelerated aging in the near future. When this problem is faced, you can touch the stone of Japan again, absorb advanced experience, and abandon the dross.

For some companies, A may invest huge amounts of money in research and development, making the original beautiful financial report a mess. B was ordered to save the building from collapse in the face of danger, but good news happened to be heard in the laboratory, B was successful and A loved anyone.

The next day, at 8 o'clock in the morning, some people from the Third Capital, Lizard Man, Strategy Group and Finance Group held a conference call, and the theme was to discuss the list of pharmaceutical companies worth investing in.

While making fun of it, Nan Yi also knew the difficulty of drug research and development. Shengchen Pharmaceutical has been almost ten years in a blink of an eye and its profits have always been good. But if you want to invest in breakthrough drug research and development, you are really unable to meet the difficulties and will have a lot of resistance.

Takeda is a typical representative of Japanese pharmaceutical companies, and it can also be said to be a weather vane. With Takeda's expansion, other Japanese pharmaceutical companies will keep up. Many Japanese pharmaceutical companies hold patented drugs with international competitiveness. After their international expansion strategy is launched, they believe that their revenue will increase dramatically.

As for whether we can innovate in imitation, it is hard to say. After all, the problem of too high investment in R&D and too high risks cannot be avoided, even if it is just improvement.

However, the production of generic drugs requires that the dosage, safety, efficacy, quality, effect and indication are almost exactly the same as imported drugs, that is, the consistency of the drugs.

It is very effective in both America and Europe. Once you get it, you will face a situation where you are not accommodating the environment. It is precisely because the domestic market is different from other countries and has its own strong personality characteristics, which has become one of the main reasons why the Nan family's industries are divided into China and the other two large areas.

Revenue is both connected with profits and stock prices. In the upcoming wave of internationalization of Japanese pharmaceutical companies, there are many benefits. Nanshi can completely make a combination of punches - the third capital, Lizard Man invests in Japanese pharmaceutical companies, PY Securities operates the stock market, and if possible, it can also short a certain pharmaceutical company. After all, the probability of drug accidents is quite high, especially when someone pushes it.

There are drug tariffs in every country, the highest is about 50%, and the lowest is 0. The purpose of collecting tariffs is very simple. First, to protect the development of relevant industries in the country, and second, to increase taxes, but the first point is easy to be useless and do nothing.

At 10 o'clock in the evening, Nanyi was also listening to a joint meeting held by several major pharmaceutical giants remotely.

As of now, Japan is already the country with the highest aging level in the world. In the 25 years from the 1960s to the 1980s, the proportion of the elderly population over 65 years old increased by 5 points. From 1980 to 1995, Japan accelerated aging period, and the proportion of the elderly population increased from less than 9% to nearly 15%.

Reform and opening up is about feeling the stones across the river. The stones being touched include the United States, Britain, Germany, Japan, etc. Both the economy and medical care are constantly absorbing the experience of these pioneers and making them use for their own use. For the medical industry in medical care, Japan is a good benchmark for China.

A representative of a pharmaceutical company has put forward a differentiated study to reduce competition among friendly companies. The general meaning is that every giant has its own field of expertise, restrain each other a little, don’t stretch your hands too long, and keep a little bit of your own...

For Chinese pharmaceutical companies, the lack of strength to invest in patented drug research and development is one aspect, and the lack of motivation is another aspect. In addition to the pharmaceutical companies themselves, insurance is also deeply restricting the development of patented drugs.

The two countries have great similarities in population structure, medical policies, economic and cultural background, etc., so the trajectory and experience of Japan's pharmaceutical industry are of great reference value to China.

The list is very long, with giants such as Merck, Wyeth, Hecht, Ciba Gargie, Bayer, Pfizer, Warner Lambert, Abbott, Eli Lilly, Bristol-My, SKK, PK, Sanders, and Roche. The reason why the financial team is also involved is that these giants cannot just invest if they want to invest. In short, if they can invest, they can enter the secondary market if they can.

For pharmaceutical companies, the market risk of making patented drugs is indeed very high. If pharmaceutical companies want to develop new drugs, their technology and technology determine whether they can be done. Whether they can be done well, the market and interests determine whether they want to do it.

Due to the high initial investment cost and the patent protection lasts only 20 years, this has led to the generally high pricing of patented drugs.

This is not how noble Nan Yi is, but that he has a strong foundation and can withstand it. Moreover, if "B" is a good choice, when shareholders burn all their money, they will sell Shengchen Pharmaceutical at a low risk. If there is a bright future for research and development, Nan Yi Dake will acquire the mess with full capital, and then spend money to write a story of perseverance and carrying the burden forward, and finally ushering in a miracle moment.

There is no way, the cost and risk of drug research and development are very high. The revenue of several giants is often over 10 billion US dollars, but the actual profit ratio that can be put into the pocket is not high. Most of the funds have to be invested in research and development. If you have a weak water of 3,000, you can only get a drink, and you will not be favored by most businessmen with ideals and aspirations.

In terms of innovation, Japan has gradually moved from Me-Better (innovation in imitation) to the international Best In Class (optimal in similar categories); while China has shown signs of the Me-Better model, but it has the influence of the argument that it is better to buy than to create, and the reduction of financial subsidies for medical care in recent years, hospitals have embarked on the road of "using medicine to support medical care". While medical representatives usher in a golden period of wealth, import patented drugs will probably appear first, despite the domestic imitation.

For other companies, it’s better not to think about it, just take a shower and go to bed. It’s more practical to break apart a few pounds and add some benefits to workers. Add less corn flour to cold medicine, and don’t add Western medicine to Chinese medicine brands. You can also be considered a good person.

This model is low-risk and high-yield, and is very popular with some people. Now there is a certain weight loss drug manager on the market. The manager of the advertising drug is also the manager of the advertising drug. He gathered a group of top Chinese students. Everyone sat together to brainstorm the efficacy and cases, repeatedly pondered the ratio of each word, carefully considered each punctuation mark, and tried to make the weight loss drug the best effect.

Since generic drugs produced at low cost meet the standards, who is willing to spend a lot of money on production processes and technology research and development?

Process and R&D obviously cannot play a sufficient role in promoting the industry, and sales are replaced by them. Whoever advertises well will sell well. Major pharmaceutical companies focus on marketing rather than making a good medicine.

The so-called similar drug pricing method will price the daily expenses of new drugs to be consistent with the expenses of similar drugs, and on this basis, give a premium based on innovation, practicality, market size and pediatric application.

Although patented drugs have higher technical standards, from a commercial perspective, generic drugs have low cost and low returns, and are relatively affordable. However, the R&D investment cost of patented drugs is relatively high and the R&D cycle is longer, which is a high-risk and high-reward production model.

There is a high probability that the Indonesian rupiah will usher in a big depreciation. The funds raised by Teng Bilian will be borrowed and loaned to Indonesia in the name of billions of international loans should be operational. The handling fee is 50 billion, the loan will be calculated for three years, and the interest will be calculated for 86 billion. Can the Indonesian rupiah more than double?

With questions, Nan Yi typing on the keyboard a few times and recalling information about Indonesia...

It is not easy to develop new drugs with breakthrough significance. The prices of drugs are limited, and the operating environment of Japanese pharmaceutical companies has been put into pressure, which is particularly serious for small businesses. The deteriorating operating environment has led to small-scale pharmaceutical companies having to withdraw from the market.

A drug with a total sales of tens of billions of dollars may be as low as only one or two billion during the patent period. If it is spread to twenty years, an investment may not beat low-risk financial products.

Nan Yi was listening for a whole morning and did not express his opinion.

In the afternoon, Nanyi continued to listen to a conference call, with the theme of predicting the possible situation after the foreseeable financial crisis in Southeast Asia and even Asia, with the focus on which countries would seek help from the International Monetary Fund.

The International Monetary Fund has four good medicines: privatization, capital market liberalization, market pricing, and poverty reduction strategies free trade.

No matter which country seeks help from the International Monetary Fund, it means opportunities and great opportunities for capital.
Chapter completed!